Outlicensing

Molecule
Dosage Form
Strength
Development Status
Dossier Availability
ATC Group
No results matching you criteria!

ABACAVIR SULFATE + LAMIVUDINE

Dosage Form:
Film-coated tablet
Strength:

600 mg + 300 mg

Development Status:
Ready
Dossier Availability:
Launched
ATC Group:
Anti-infectives for systemic use

ACETYLSALICYLIC ACID

Dosage Form:
Tablet
Strength:

100 MG

Development Status:
Ready
Dossier Availability:
Filed in EU
ATC Group:
Various ATC structures

ACETYLSALICYLIC ACID

Dosage Form:
Tablet
Strength:

500 mg

Development Status:
Ready
Dossier Availability:
Launched
ATC Group:
Various ATC structures

AGOMELATINE

Dosage Form:
Film-coated tablet
Strength:

25 mg

Development Status:
Ready
Dossier Availability:
EU registered
ATC Group:
Antidepressant

AMLODIPINE

Dosage Form:
Tablet
Strength:

2.5 mg, 5 mg, 10 mg

Development Status:
Ready
Dossier Availability:
Launched
ATC Group:
Cardiovascular system

AMLODIPINE BESILATE + CANDESARTAN CILEXETIL

Dosage Form:
Tablet
Strength:

5 mg + 8 mg, 10 mg + 16 mg

Development Status:
Ready
Dossier Availability:
Launched
ATC Group:
Cardiovascular system

AMLODIPINE BESILATE + CANDESARTAN CILEXETIL

Dosage Form:
Tablet
Strength:

5 mg + 16 mg

Development Status:
Ready
Dossier Availability:
Launched
ATC Group:
Cardiovascular system

AMLODIPINE BESILATE + INDAPAMIDE + PERINDOPRIL ERBUMINE

Dosage Form:
Tablet
Strength:

5 mg + 1.25 mg + 4 mg, 10 mg + 1.25 mg + 4 mg, 5 mg + 2.5 mg + 8 mg, 10 mg + 2.5 mg + 8 mg

Development Status:
Ready
Dossier Availability:
-
ATC Group:
Cardiovascular system

AMLODIPINE BESILATE + PERINDOPRIL ERBUMINE

Dosage Form:
Tablet
Strength:

5 mg + 4 mg, 10 mg + 4 mg, 5 mg + 8 mg, 10 mg + 8 mg

Development Status:
Ready
Dossier Availability:
-
ATC Group:
Cardiovascular system

AMLODIPINE BESILATE + VALSARTAN

Dosage Form:
Film-coated tablet
Strength:

5 mg + 80 mg, 5 mg + 160 mg, 10 mg + 160 mg

Development Status:
Ready
Dossier Availability:
EU registered
ATC Group:
Cardiovascular system

APIXABAN

Dosage Form:
Film-coated tablet
Strength:

2.5 mg, 5 mg

Development Status:
Ready
Dossier Availability:
Filed in EU
ATC Group:
Blood and blood forming organs

APREMILAST

Dosage Form:
Film-coated tablet
Strength:

10 mg, 20 mg, 30 mg

Development Status:
Ready
Dossier Availability:
Filed in EU
ATC Group:
Dermatological drugs

ATAZANAVIR

Dosage Form:
Capsule hard gastro-resistant
Strength:

50 mg, 100 mg 150 mg, 200 mg

Development Status:
Ready
Dossier Availability:
Launched
ATC Group:
Anti-infectives for systemic use

ATORVASTATIN

Dosage Form:
Oral suspension
Strength:

4 mg/ml

Development Status:
Ongoing
Dossier Availability:
Q3 2025
ATC Group:
Cardiovascular system

ATORVASTATIN CALCIUM

Dosage Form:
Film-coated tablet
Strength:

10 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg

Development Status:
Ready
Dossier Availability:
Filed in EU
ATC Group:
Cardiovascular system

BISOPROLOL

Dosage Form:
Oral solution
Strength:

0.5 mg/ml

Development Status:
Ongoing
Dossier Availability:
Q1 2024
ATC Group:
Cardiovascular system

DAPAGLIFLOZIN

Dosage Form:
Film-coated tablet
Strength:

5 mg, 10 mg

Development Status:
Ongoing
Dossier Availability:
Q2 2025
ATC Group:
Alimentary tract and metabolism

DAPAGLIFLOZIN + METFORMIN

Dosage Form:
Film-coated tablet
Strength:

5 mg + 850 mg, 5 mg + 1000 mg

Development Status:
Ongoing
Dossier Availability:
Q3 2025
ATC Group:
Alimentary tract and metabolism

DASATINIB (pH resistant)

Dosage Form:
Film-coated tablet
Strength:

15.8 mg, 35.5 mg, 55.3 mg, 63.2 mg, 79 mg, 110.6 mg

Development Status:
Ready
Dossier Availability:
EU registered
ATC Group:
Antineoplastic and immunomodulating agents

DEFERASIROX

Dosage Form:
Film-coated tablet
Strength:

90 mg, 180 mg, 360 mg

Development Status:
Ready
Dossier Availability:
EU registered
ATC Group:
Various ATC structures

DEXAMETHASONE

Dosage Form:
Solution for injection
Strength:

4 mg/ml

Development Status:
Ongoing
Dossier Availability:
Q4 2025
ATC Group:
Various ATC structures

DEXIBUPROFEN

Dosage Form:
Film-coated tablet
Strength:

200 mg, 300 mg, 400 mg

Development Status:
Ongoing
Dossier Availability:
Q3 2024
ATC Group:
Nervous system

DOLUTEGRAVIR

Dosage Form:
Film-coated tablet
Strength:

50 mg

Development Status:
Ongoing
Dossier Availability:
Q2 2025
ATC Group:
Anti-infectives for systemic use

DOLUTEGRAVIR + LAMIVUDINE

Dosage Form:
Film-coated tablet
Strength:

50 mg + 300 mg

Development Status:
Ongoing
Dossier Availability:
Q2 2026
ATC Group:
Anti-infectives for systemic use

DROSPIRENONE + ESTRADIOL

Dosage Form:
Film-coated tablet
Strength:

2 mg + 1 mg

Development Status:
Ready
Dossier Availability:
Q1 2023
ATC Group:
Hormone replacement therapy

EDOXABAN

Dosage Form:
Film-coated tablet
Strength:

15 mg, 30 mg, 60 mg

Development Status:
Ready
Dossier Availability:
Filed in EU
ATC Group:
Blood and blood forming organs

EMPAGLIFLOZIN

Dosage Form:
Film-coated tablet
Strength:

10 mg, 25 mg

Development Status:
Ongoing
Dossier Availability:
Q1 2025
ATC Group:
Alimentary tract and metabolism

EMPAGLIFLOZIN + METFORMIN

Dosage Form:
Film-coated tablet
Strength:

5mg + 850mg, 12,5mg + 850 mg, 5mg + 1000mg, 12,5mg + 1000 mg

Development Status:
Ongoing
Dossier Availability:
Q4 2026
ATC Group:
Alimentary tract and metabolism

EMTRICITABINE + RILPIVIRINE + TENOFOVIR ALAFENAMIDE

Dosage Form:
Film-coated tablet
Strength:

200 mg + 25 mg + 25 mg, 200 mg + 27.5 mg + 28 mg

Development Status:
Ongoing
Dossier Availability:
Q4 2024
ATC Group:
Antivirotic

EMTRICITABINE + TENOFOVIR ALAFENAMIDE

Dosage Form:
Film-coated tablet
Strength:

200 mg + 10 mg, 200 mg + 25 mg

Development Status:
Ongoing
Dossier Availability:
Q3 2024
ATC Group:
Antivirotic

ETORICOXIB

Dosage Form:
Film-coated tablet
Strength:

30 mg, 60 mg, 90 mg, 120 mg

Development Status:
Ready
Dossier Availability:
Launched
ATC Group:
Musculoskeletal system

FINGOLIMOD

Dosage Form:
Capsule, hard
Strength:

0.5 mg

Development Status:
Ready
Dossier Availability:
Launched
ATC Group:
Multiple sclerosis

HYDROCHLOROTHIAZIDE+ LOSARTAN POTASSIUM

Dosage Form:
Film-coated tablet
Strength:

12.5 mg + 50 mg, 12.5 mg + 100 mg, 25 mg + 100 mg

Development Status:
Ready
Dossier Availability:
Launched
ATC Group:
Cardiovascular system

IBANDRONATE SODIUM MONOHYDRATE

Dosage Form:
Film-coated tablet
Strength:

150 mg

Development Status:
Ready
Dossier Availability:
Launched
ATC Group:
Musculoskeletal system

IBUPROFEN

Dosage Form:
Film-coated tablet
Strength:

200 mg, 400 mg, 600 mg, 800 mg

Development Status:
Ready
Dossier Availability:
EU registered
ATC Group:
Nervous system

IBUPROFEN

Dosage Form:
Oral suspension
Strength:

100 mg/5 ml (2%), 200 mg/5 ml (4%)

Development Status:
Ongoing
Dossier Availability:
Q4 2025
ATC Group:
Nervous system

IBUPROFEN IR + SR OTC

Dosage Form:
Tablet
Strength:

200 IR+200 XR

Development Status:
Ongoing
Dossier Availability:
Q4 2023
ATC Group:
Nervous system

IBUPROFEN LYSINATE

Dosage Form:
Film-coated tablet
Strength:

400 MG

Development Status:
Ready
Dossier Availability:
Ready
ATC Group:
Nervous system

LACOSAMIDE

Dosage Form:
Film-coated tablet
Strength:

50 mg, 100 mg 150 mg, 200 mg

Development Status:
Ready
Dossier Availability:
-
ATC Group:
Nervous system

LEVETIRACETAM

Dosage Form:
Film-coated tablet
Strength:

250 mg, 500 mg, 750 mg, 1000 mg

Development Status:
Ready
Dossier Availability:
Launched
ATC Group:
Nervous system

LINAGLIPTIN

Dosage Form:
Film-coated tablet
Strength:

5 mg

Development Status:
Ready
Dossier Availability:
EU registered
ATC Group:
Alimentary tract and metabolism

METAMIZOLE SODIUM

Dosage Form:
Film-coated tablet
Strength:

500 mg

Development Status:
Ready
Dossier Availability:
Filed in EU
ATC Group:
Nervous system

METAMIZOLE SODIUM

Dosage Form:
Injection
Strength:

500 mg/ml (2 ml)

Development Status:
Ready
Dossier Availability:
Filed in EU
ATC Group:
Nervous system

METFORMIN HYDROCHLORIDE

Dosage Form:
Film-coated tablet
Strength:

500 mg, 850 mg, 1000 mg

Development Status:
Ready
Dossier Availability:
EU registered
ATC Group:
Alimentary tract and metabolism

NOREPINEPHRINE

Dosage Form:
Injection
Strength:

1 mg / 1 ml

Development Status:
Ready
Dossier Availability:
Filed in EU
ATC Group:
Cardiovascular system

OMEPRAZOLE + ANTACIDUM

Dosage Form:
Capsule
Strength:

20 mg

Development Status:
Ready
Dossier Availability:
Filed in EU
ATC Group:
Alimentary tract and metabolism

PARACETAMOL

Dosage Form:
Tablet
Strength:

500 mg, 1000 mg

Development Status:
Ready
Dossier Availability:
EU registered
ATC Group:
Nervous system

PERINDOPRIL ARGININE

Dosage Form:
Film-coated tablet
Strength:

2.5 mg, 5 mg, 10 mg

Development Status:
Ready
Dossier Availability:
-
ATC Group:
Cardiovascular system

PRASUGREL HYDROCHLORIDE

Dosage Form:
Film-coated tablet
Strength:

10 mg

Development Status:
Ready
Dossier Availability:
-
ATC Group:
Blood and blood forming organs

RILMENIDINE

Dosage Form:
Tablet
Strength:

1 mg

Development Status:
Ready
Dossier Availability:
Launched
ATC Group:
Cardiovascular system

RIVAROXABAN

Dosage Form:
Film-coated tablet
Strength:

2.5 mg, 10 mg, 15 mg, 20 mg

Development Status:
Ready
Dossier Availability:
EU registered
ATC Group:
Blood and blood forming organs

RIVAROXABAN

Dosage Form:
Capsule, hard
Strength:

2.5 mg, 10 mg, 15 mg, 20 mg

Development Status:
Ready
Dossier Availability:
EU registered
ATC Group:
Blood and blood forming organs

RIVAROXABAN suspension

Dosage Form:
Oral suspension
Strength:

5 mg/ml

Development Status:
Ready
Dossier Availability:
Filed in EU
ATC Group:
Blood and blood forming organs

RIVAROXABAN (reliable absorption)

Dosage Form:
Capsule, hard
Strength:

15 mg, 25 mg

Development Status:
Ongoing
Dossier Availability:
Q4 2024
ATC Group:
Blood and blood forming organs

ROSUVASTATIN

Dosage Form:
Film-coated tablet
Strength:

15 mg, 30 mg

Development Status:
Ready
Dossier Availability:
Launched
ATC Group:
Cardiovascular system

ROSUVASTATIN CALCIUM

Dosage Form:
Film-coated tablet
Strength:

5 mg, 10 mg, 15mg, 20 mg, 30 mg, 40 mg

Development Status:
Ready
Dossier Availability:
Launched
ATC Group:
Cardiovascular system

SACUBITRIL + VALSARTAN

Dosage Form:
Film-coated tablet
Strength:

24 mg + 26 mg, 49 mg + 51 mg, 97 mg + 103 mg

Development Status:
Ongoing
Dossier Availability:
Q3 2024
ATC Group:
Cardiovascular system

SERTRALINE

Dosage Form:
Film-coated tablet
Strength:

25 mg

Development Status:
Ready
Dossier Availability:
EU registered
ATC Group:
Nervous system

SERTRALINE

Dosage Form:
Film-coated tablet
Strength:

50 mg, 100 mg

Development Status:
Ready
Dossier Availability:
Filed in EU
ATC Group:
Nervous system

SITAGLIPTIN PHOSPHATE

Dosage Form:
Film-coated tablet
Strength:

25 mg, 50 mg, 100 mg

Development Status:
Ready
Dossier Availability:
-
ATC Group:
Alimentary tract and metabolism

SITAGLIPTIN PHOSPHATE + METFORMIN

Dosage Form:
Film-coated tablet
Strength:

50 mg + 850 mg, 50 mg + 1000 mg

Development Status:
Ready
Dossier Availability:
-
ATC Group:
Alimentary tract and metabolism

SOLIFENACIN SUCCINATE

Dosage Form:
Film-coated tablet
Strength:

5 mg, 10 mg

Development Status:
Ready
Dossier Availability:
Launched
ATC Group:
Genitourinary system and reproductive hormones

TAMSULOSIN HYDROCHLORIDE

Dosage Form:
Modified-release capsule, hard
Strength:

0.4 mg

Development Status:
Ready
Dossier Availability:
Launched
ATC Group:
Genitourinary system and reproductive hormones

TICAGRELOR

Dosage Form:
Film-coated tablet
Strength:

60 mg, 90 mg

Development Status:
Ready
Dossier Availability:
EU registered
ATC Group:
Blood and blood forming organs

TORASEMIDE

Dosage Form:
Tablet
Strength:

2.5 mg, 10 mg, 15 mg, 20 mg

Development Status:
Ready
Dossier Availability:
Filed in EU
ATC Group:
Cardiovascular system

VARDENAFIL HYDROCHLORIDE TRIHYDRATE

Dosage Form:
Film-coated tablet
Strength:

5 mg, 10 mg, 20 mg

Development Status:
Ready
Dossier Availability:
Launched
ATC Group:
Genitourinary system and reproductive hormones

VILDAGLIPTIN

Dosage Form:
Tablet
Strength:

50 mg

Development Status:
Ready
Dossier Availability:
EU registered
ATC Group:
Alimentary tract and metabolism

VORTIOXETINE

Dosage Form:
Film-coated tablet
Strength:

5 mg, 10 mg, 15 mg, 20 mg

Development Status:
Ongoing
Dossier Availability:
Q4 2024
ATC Group:
Nervous system

DISCLAIMER:

Any disposal with the product, including but not limited to the development, sale and offer for sale of products and related processes identified within this catalogue is performed by Zentiva only in those territories where it is permissible by applicable patent law; in particular, but not limited to Art. 10 EC Directive 2001/83and any other limitation imposed to Zentiva by contracts with 3rd parties . This catalogue shall not constitute an offer for the sale of products and processes for the territories where an offer for sale or sale is not permissible by law orby contracts between Zentiva and 3rd parties. Zentiva expressly disclaims any liability for damages resulting from or arising out of the unauthorised use of such products and related processes.

*4B Zone stability can be fulfilled upon request if not available at the moment